Dr Mostafa Hamed
About
Mostafa Hamed is a scientist in the department of Drug Design and Optimization (DDOP). He is a medicinal chemist whose research focuses on the development of novel anti-infective and antivirulence agents, and has contributed to multiple drug discovery projects. Mostafa studied Pharmacy at Misr University for Science and Technology (Egypt) and earned his Master’s degree in Medicinal Chemistry from Cairo University. In 2013, he received his Ph.D. in Medicinal Chemistry from Saarland University, where he conducted his research in the group of Prof. Rolf W. Hartmann.
2025
Direct monitoring of intracellular polymer degradation via BODIPY dynamic dequenching
Bassil J, Kamal M, Gabelmann A, Christoulaki A, Koch M, Hamed M, Loretz B, Gallei M, Buhler E, Lehr C, Hirsch A, Lee S (2025)
Mater. Des. 256DOI: 10.1016/j.matdes.2025.114240
Targeting isoprenoid-precursor biosynthesis in Klebsiella pneumoniae: Design, synthesis and evaluation of 1-deoxy-D-xylulose 5-phosphate synthase (DXPS) inhibitors
Eisa S, Lacour A, Johannsen S, Hamid R, Raj P, Heinz D, Hamed M, Diamanti E, Hirsch A (2025)
Bioorg. Chem. 164DOI: 10.1016/j.bioorg.2025.108877
A Novel Antimalarial Agent that Inhibits Protein Synthesis in Plasmodium falciparum
Bravo P, Diamanti E, Hamed M, Bizzarri L, Wiedemar N, Passecker A, Brancucci N, Albisetti A, Gumpp C, Illarionov B, …, Rottmann M, Hirsch A (2025)
Angew. Chem. Int. Ed.DOI: 10.1002/anie.202514085
Positive Charge in an Antimalarial Compound Unlocks Broad-Spectrum Antibacterial Activity
Braun-Cornejo M, Platteschorre M, Vries V, Bravo P, Sonawane V, Hamed M, Haupenthal J, Reiling N, Rottmann M, Piet D, …, Diamanti E, Hirsch A (2025)
JACS Au 5 (3): 1146-1156DOI: 10.1021/jacsau.4c00935
Discovery of a novel, selective CK2 inhibitor class with an unusual basic scaffold
Khalifa H, ElHady A, Liu T, Elgaher W, Filhol-Cochet O, Cochet C, Abadi A, Hamed M, Abdel-Halim M, Engel M (2025)
European journal of medicinal chemistry 282DOI: 10.1016/j.ejmech.2024.117048
From Dyrk1A inhibitors to a novel class of antiviral agents: Targeting Enterovirus EV-A71 with 2-aryl-substituted thiophene scaffolds
Keddis P, My Tu T, Scherer H, Kany A, Hafez D, Darwish S, Abadi A, Hirsch A, Engel M, Hamed M, Horng J, Abdel-Halim M (2025)
Eur. J. Med. Chem. 287DOI: 10.1016/j.ejmech.2025.117348
2024
Fragment Discovery by X-Ray Crystallographic Screening Targeting the CTP Binding Site of Pseudomonas Aeruginosa IspD
Willocx D, D'Auria L, Walsh D, Scherer H, Alhayek A, Hamed M, Borel F, Diamanti E, Hirsch A (2024)
Angew. Chem., Int. Ed. Engl.DOI: 10.1002/anie.202414615
IspE kinase as an anti-infective target: Role of a hydrophobic pocket in inhibitor binding
Hamid R, Walsh D, Diamanti E, Aguilar D, Lacour A, Hamed M, Hirsch A (2024)
Structure (London, England : 1993) 32 (12): 2390-2398DOI: 10.1016/j.str.2024.10.009
Targeting the Plasmodium falciparum IspE Enzyme
Diamanti E, Steinbach A, Carvalho L, Ropponen H, Lacour A, Hamid R, Eisa S, Bravo P, Bousis S, Illarionov B, …, Sieber S, Hirsch A (2024)
ACS omega 9 (44): 44465-44473DOI: 10.1021/acsomega.4c06038
Targeting Plasmodium falciparum IspD in the Methyl-d-erythritol Phosphate Pathway: Urea-Based Compounds with Nanomolar Potency on Target and Low-Micromolar Whole-Cell Activity
Willocx D, Bizzarri L, Alhayek A, Kannan D, Bravo P, Illarionov B, Rox K, Lohse J, Fischer M, Kany A, …, Diamanti E, Hirsch A (2024)
Journal of medicinal chemistry 67 (19): 17070-17086DOI: 10.1021/acs.jmedchem.4c00212
Two natural compounds as potential inhibitors against the Helicobacter pylori and Acinetobacter baumannii IspD enzymes
Chen X, Zhao H, Wang C, Hamed M, Shang Q, Yang Y, Diao X, Sun X, Hu W, Jiang X, …, Wu D, Zhuang J (2024)
Int. J. Antimicrob. Agents 63 (5)DOI: 10.1016/j.ijantimicag.2024.107160
Discovery and optimization of thiazole-based quorum sensing inhibitors as potent blockers of Pseudomonas aeruginosa pathogenicity
Abdelsamie A, Hamed M, Schütz C, Röhrig T, Kany A, Schmelz S, Blankenfeldt W, Hirsch A, Hartmann R, Empting M (2024)
Eur. J. Med. Chem. 276DOI: 10.1016/j.ejmech.2024.116685
Hit optimization by dynamic combinatorial chemistry on Streptococcus pneumoniae energy-coupling factor transporter ECF-PanT
Exapicheidou I, Shams A, Ibrahim H, Tsarenko A, Backenköhler M, Hamed M, Diamanti E, Volkamer A, slotboom d, Hirsch A (2024)
Chem. Commun. 60 (7): 870-873DOI: 10.1039/D3CC04738E
Development and evaluation of 2,4-disubstituted-5-aryl pyrimidine derivatives as antibacterial agents
Khalifa H, Rasheed S, Haupenthal J, Herrmann J, Mandour Y, Abadi A, Engel M, Müller R, Hirsch A, Abdel-Halim* M, Hamed* M (2024)
Archiv der PharmazieDOI: 10.1002/ardp.202300656
2023
Towards Translation of PqsR Inverse Agonists: From In Vitro Efficacy Optimization to In Vivo Proof-of-Principle
Hamed M, Abdelsamie A, Rox K, Schütz C, Kany A, Röhrig T, Schmelz S, Blankenfeldt W, Arce-Rodriguez A, Borrero-de Acuña J, …, Hartmann R, Empting M (2023)
Adv. Sci. (Online)DOI: 10.1002/advs.202204443
2022
Design, Synthesis, Antimicrobial Activity, and Molecular Docking of Some New Diclofenac Derivatives
Tolba M, Hamed M, Sayed M, Kamal El-Dean A, Abdel-Mohsen S, Ibrahim O, Elgaher W, Hirsch A, Saddik A (2022)
Polycyclic Aromatic Compounds: 1-16DOI: 10.1080/10406638.2022.2102661
Structure-Guided Optimization of Small-Molecule Folate Uptake Inhibitors Targeting the Energy-Coupling Factor Transporters
Kiefer A, Bousis S, Hamed M, Diamanti E, Haupenthal J, Hirsch A (2022)
J. Med. Chem.DOI: 10.1021/acs.jmedchem.1c02114
Design and Synthesis of Novel Bis-Imidazolyl Phenyl Butadiyne Derivatives as HCV NS5A Inhibitors
Hamdy J, Emadeldin N, Hamed M, Frakolaki E, Katsamakas S, Vassilaki N, Zoidis G, Hirsch A, Abdel-Halim M, Abadi A (2022)
Pharmaceuticals 15 (5)DOI: 10.3390/ph15050632
Novel 2,4-disubstituted quinazoline analogs as antibacterial agents with improved cytotoxicity profile: Modification of the benzenoid part
Megahed S, Rasheed S, Herrmann J, El-Hossary E, El-Shabrawy Y, Abadi A, Engel M, Müller R, Abdel-Halim M, Hamed M (2022)
Bioorg Med Chem Lett 59DOI: 10.1016/j.bmcl.2022.128531
2021
New PqsR Inverse Agonist
Schütz C, Empting M, Ahmed S, Hamed M, Hartmann R, Röhrig T, Kany A, Hirsch A (2021)
Patent A61K31/4439; A61K31/506; A61P31/04; C07D401/12; C07D403/12; (WO2021136803A1)
Novel PqsR Inverse Agonists
Hamed M, Ahmed S, Empting. M., Schütz C, Hartmann R, Röhrig T, Kany A, Hirsch A (2021)
Patent A61K31/4439; A61P31/04; C07D401/14; C07D417/14; (WO2021136805A1)
Targeting the IspD Enzyme in the MEP Pathway: Identification of a Novel Fragment Class
Diamanti E, Hamed M, Lacour A, Bravo P, Illarionov B, Fischer M, Rottmann M, Witschel M, Hirsch A (2021)
ChemMedChemDOI: 10.1002/cmdc.202100679
Redesigning of the cap conformation and symmetry of the diphenylethyne core to yield highly potent pan-genotypic NS5A inhibitors with high potency and high resistance barrier
Abdallah M, Hamed M, Frakolaki E, Katsamakas S, Vassilaki N, Bartenschlager R, Zoidis G, Hirsch A, Abdel-Halim M, Abadi A (2021)
European journal of medicinal chemistryDOI: 10.1016/j.ejmech.2021.114034
Expanding the Myxochelin Natural Product Family by Nicotinic Acid Containing Congeners
Frank N, Széles M, Akone S, Rasheed S, Hüttel S, Frewert S, Hamed M, Herrmann J, Schuler S, Hirsch A, Müller R (2021)
Molecules 26 (16)DOI: 10.3390/molecules26164929
A New PqsR Inverse Agonist Potentiates Tobramycin Efficacy to Eradicate Pseudomonas aeruginosa Biofilms
Schütz C, Ho D, Hamed M, Abdelsamie A, Röhrig T, Herr C, Kany A, Rox K, Schmelz S, Siebenbürger L, …, Lehr C, Empting M (2021)
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 8 (12)DOI: 10.1002/advs.202004369
2020
Cystobactamid 507: Concise Synthesis, Mode of Action, and Optimization toward More Potent Antibiotics
Elgaher W, Hamed M, Baumann S, Herrmann J, Siebenbürger L, Krull J, Cirnski K, Kirschning A, Brönstrup M, Müller R, Hartmann R (2020)
Chem. Eur. J. 26 (32): 7219-7225DOI: 10.1002/chem.202000117
Synthetic studies of cystobactamids as antibiotics and bacterial imaging carriers lead to compounds with high in vivo efficacy
Testolin G, Cirnski K, Rox K, Prochnow H, Fetz V, Grandclaudon C, Mollner T, Baiyoumy A, Ritter A, Leitner C, …, Müller R, Brönstrup M (2020)
Chemical Science 11 (5): 1316-1334DOI: 10.1039/C9SC04769G
Novel PqsR Inverse Agonists
Hamed M, Ahmed S, Empting. M., Schütz C, Hartmann R, Röhrig T, Kany A, Hirsch A (2020)
Patent (EP20150119)
2015
Novel PqsR Inverse Agonists
Hamed M (2015)
Patent (EP 201523196)
Synthesis and biological evaluation of cystobactamid 507: a bacterial topoisomerase inhibitor from Cystobacter sp
Moreno M, Elgaher W, Herrmann J, Schläger N, Hamed M, Baumann S, Müller R, Hartmann R, Kirschning A (2015)
Synlett 26 (9): 1175-1178DOI: 10.1055/s-0034-1380509